<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id><journal-id journal-id-type="publisher-id">BPH</journal-id><journal-title-group><journal-title>British Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26773325</article-id><article-id pub-id-type="pmc">4842915</article-id><article-id pub-id-type="doi">10.1111/bph.13433</article-id><article-id pub-id-type="publisher-id">BPH13433</article-id><article-id pub-id-type="other">2015-BJP-0595-RP.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Papers</subject></subj-group></article-categories><title-group><article-title>Safety, pharmacokinetics and pharmacodynamics of the anti&#x02010;hepcidin Spiegelmer lexaptepid pegol in healthy subjects</article-title><alt-title alt-title-type="right-running-head">Safety, PK and PD of lexaptepid pegol in healthy subjects</alt-title><alt-title alt-title-type="left-running-head">M Boyce et al.</alt-title></title-group><contrib-group><contrib id="bph13433-cr-0001" contrib-type="author"><name><surname>Boyce</surname><given-names>M</given-names></name><xref ref-type="aff" rid="bph13433-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bph13433-cr-0002" contrib-type="author"><name><surname>Warrington</surname><given-names>S</given-names></name><xref ref-type="aff" rid="bph13433-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bph13433-cr-0003" contrib-type="author"><name><surname>Cortezi</surname><given-names>B</given-names></name><xref ref-type="aff" rid="bph13433-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bph13433-cr-0004" contrib-type="author"><name><surname>Z&#x000f6;llner</surname><given-names>S</given-names></name><xref ref-type="aff" rid="bph13433-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bph13433-cr-0005" contrib-type="author"><name><surname>Vaul&#x000e9;on</surname><given-names>S</given-names></name><xref ref-type="aff" rid="bph13433-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bph13433-cr-0006" contrib-type="author"><name><surname>Swinkels</surname><given-names>D W</given-names></name><xref ref-type="aff" rid="bph13433-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bph13433-cr-0007" contrib-type="author"><name><surname>Summo</surname><given-names>L</given-names></name><xref ref-type="aff" rid="bph13433-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bph13433-cr-0008" contrib-type="author"><name><surname>Schwoebel</surname><given-names>F</given-names></name><xref ref-type="aff" rid="bph13433-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bph13433-cr-0009" contrib-type="author" corresp="yes"><name><surname>Riecke</surname><given-names>K</given-names></name><xref ref-type="aff" rid="bph13433-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="bph13433-aff-0001" content-type="private-address"><label><sup>1</sup></label><institution>Hammersmith Medicines Research</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="bph13433-aff-0002" content-type="private-address"><label><sup>2</sup></label><institution>NOXXON Pharma AG</institution><named-content content-type="city">Berlin</named-content><country country="DE">Germany</country></aff><aff id="bph13433-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Hepcidinanalysis.com</named-content><institution>Radboud University Nijmegen Medical Center</institution><named-content content-type="city">Nijmegen</named-content><country country="NL">The Netherlands</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence Kai Riecke, NOXXON Pharma AG, Max&#x02010;Dohrn&#x02010;Stra&#x000df;e 8&#x02010;10, 10589 Berlin, Germany. E&#x02010;mail: <email>clinic@noxxon.com</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>08</day><month>4</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>173</volume><issue>10</issue><issue-id pub-id-type="doi">10.1111/bph.v173.10</issue-id><issue-title content-type="special-issue-title">Themed Section: Chinese Innovation in Cardiovascular Drug Discovery. Guest Editors: Xin Wang, Yong Ji and Baofeng Yang</issue-title><fpage>1580</fpage><lpage>1588</lpage><history><date date-type="received"><day>04</day><month>6</month><year>2015</year></date><date date-type="rev-recd"><day>11</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>1</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 The British Pharmacological Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. British Journal of Pharmacology published by John Wiley &#x00026; Sons Ltd on behalf of British Pharmacological Society.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BPH-173-1580.pdf"/><abstract><sec id="bph13433-sec-0001"><title>Background and Purpose</title><p>Anaemia of chronic disease is characterized by impaired erythropoiesis due to functional iron deficiency, often caused by excessive hepcidin. Lexaptepid pegol, a pegylated structured <sc>l</sc>&#x02010;oligoribonucleotide, binds and inactivates hepcidin.</p></sec><sec id="bph13433-sec-0002"><title>Experimental Approach</title><p>We conducted a placebo&#x02010;controlled study on the safety, pharmacokinetics and pharmacodynamics of lexaptepid after single and repeated i.v. and s.c. administration to 64 healthy subjects at doses from 0.3 to 4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>.</p></sec><sec id="bph13433-sec-0003"><title>Key Results</title><p>After treatment with lexaptepid, serum iron concentration and transferrin increased dose&#x02010;dependently. Iron increased from approximately 20&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup> at baseline by 67% at 8&#x000a0;h after i.v. infusion of 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid. The pharmacokinetics showed dose&#x02010;proportional increases in peak plasma concentrations and moderately over&#x02010;proportional increases in systemic exposure. Lexaptepid had no effect on hepcidin production or anti&#x02010;drug antibodies. Treatment with lexaptepid was generally safe and well tolerated, with mild and transient transaminase increases at doses &#x02265;2.4&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> and with local injection site reactions after s.c. but not after i.v. administration.</p></sec><sec id="bph13433-sec-0004"><title>Conclusions and Implications</title><p>Lexaptepid pegol inhibited hepcidin and dose&#x02010;dependently raised serum iron and transferrin saturation. The compound is being further developed to treat anaemia of chronic disease.</p></sec></abstract><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bph13433</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.8 mode:remove_FC converted:30.11.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bph13433-cit-0000">
<string-name>
<surname>Boyce</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Warrington</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Cortezi</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Z&#x000f6;llner</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Vaul&#x000e9;on</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Swinkels</surname>, <given-names>D. W.</given-names>
</string-name>, <string-name>
<surname>Summo</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Schwoebel</surname>, <given-names>F.</given-names>
</string-name>, and <string-name>
<surname>Riecke</surname>, <given-names>K.</given-names>
</string-name> (<year>2016</year>) <article-title>Safety, pharmacokinetics and pharmacodynamics of the anti&#x02010;hepcidin Spiegelmer lexaptepid pegol in healthy subjects</article-title>. <source>British Journal of Pharmacology</source>, <volume>173</volume>: <fpage>1580</fpage>&#x02013;<lpage>1588</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/bph.13433">10.1111/bph.13433</ext-link>.<pub-id pub-id-type="pmid">26773325</pub-id></mixed-citation>
</p></notes></front><body><def-list list-content="abbreviations" id="bph13433-dl-0001"><title>Abbreviations</title><def-item><term id="bph13433-li-0001">ACD</term><def id="bph13433-li-0002"><p>anaemia of chronic disease</p></def></def-item><def-item><term id="bph13433-li-0003">AUC<sub>0&#x02013;tz</sub></term><def id="bph13433-li-0004"><p>area under the plasma concentration&#x02013;time curve to the last observed concentration</p></def></def-item><def-item><term id="bph13433-li-0005">CL</term><def id="bph13433-li-0006"><p>total body clearance of drug from plasma</p></def></def-item><def-item><term id="bph13433-li-0007">CL<sub>R</sub></term><def id="bph13433-li-0008"><p>renal clearance</p></def></def-item><def-item><term id="bph13433-li-0009"><italic>C</italic><sub>max</sub></term><def id="bph13433-li-0010"><p>maximum plasma concentration</p></def></def-item><def-item><term id="bph13433-li-0011">PEG</term><def id="bph13433-li-0012"><p>polyethylene glycol</p></def></def-item><def-item><term id="bph13433-li-0013">PK</term><def id="bph13433-li-0014"><p>pharmacokinetics</p></def></def-item><def-item><term id="bph13433-li-0015"><italic>t</italic><sub>1/2,ini</sub></term><def id="bph13433-li-0016"><p>initial elimination half&#x02010;life</p></def></def-item><def-item><term id="bph13433-li-0017"><italic>t</italic><sub>1/2</sub></term><def id="bph13433-li-0018"><p>terminal elimination half&#x02010;life</p></def></def-item><def-item><term id="bph13433-li-0019"><italic>V</italic><sub>ss</sub></term><def id="bph13433-li-0020"><p>apparent volume of distribution at steady state</p></def></def-item></def-list><sec id="bph13433-sec-0005"><title>Tables of Links</title><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><table frame="hsides" rules="cols"><col align="left" style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>TARGETS</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Transporters</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1194">Ferroportin, SLC40A1</ext-link>
</td></tr></tbody></table><table frame="hsides" rules="cols"><col align="left" style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>LIGANDS</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&#x00026;ligandId=5378">Hepcidin</ext-link>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&#x00026;ligandId=4977">IL&#x02010;12</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&#x00026;ligandId=4998">IL&#x02010;6</ext-link>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&#x00026;ligandId=6881">Tocilizumab</ext-link>
</td></tr></tbody></table><table-wrap-foot><fn id="bph13433-note-0100"><p>These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in <ext-link ext-link-type="uri" xlink:href="http://www.guidetopharmacology.org">http://www.guidetopharmacology.org</ext-link>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson <italic>et al.</italic>, <xref rid="bph13433-bib-0016" ref-type="ref">2014</xref>) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander <italic>et al.</italic>, <xref rid="bph13433-bib-0001" ref-type="ref">2015</xref>).</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="bph13433-sec-0006"><title>Introduction</title><p>Hepcidin, a 25&#x02010;amino&#x02010;acid peptide produced by the liver (Krause <italic>et al.</italic>, <xref rid="bph13433-bib-0009" ref-type="ref">2000</xref>; Park <italic>et al.</italic>, <xref rid="bph13433-bib-0015" ref-type="ref">2001</xref>; Pigeon <italic>et al.</italic>, <xref rid="bph13433-bib-0017" ref-type="ref">2001</xref>), has emerged as the key regulator of systemic iron homeostasis (Ganz, <xref rid="bph13433-bib-0005" ref-type="ref">2003</xref>; Roy <italic>et al.</italic>, <xref rid="bph13433-bib-0020" ref-type="ref">2007</xref>). It inhibits the release of intracellular iron from duodenal enterocytes, hepatocytes and reticuloendothelial cells by binding to the membrane iron exporter ferroportin, which leads to its internalization and inactivation (Nemeth <italic>et al.</italic>, <xref rid="bph13433-bib-0014" ref-type="ref">2004</xref>; Nemeth and Ganz, <xref rid="bph13433-bib-0013" ref-type="ref">2006</xref>). Hepcidin is degraded intracellularly after binding to ferroportin (Preza <italic>et al.</italic>, <xref rid="bph13433-bib-0018" ref-type="ref">2013</xref>), while fractional urinary excretion is low (Swinkels <italic>et al.</italic>, <xref rid="bph13433-bib-0023" ref-type="ref">2008</xref>). Hepcidin expression is induced by circulating iron, body iron stores and by inflammation where it is thought to contribute to host defence. Hepcidin expression is inhibited by erythropoietic activity through certain factors such as growth differentiation factor 15 (Tanno <italic>et al.</italic>, <xref rid="bph13433-bib-0025" ref-type="ref">2007</xref>), twisted gastrulation protein homologue 1 (Tanno <italic>et al.</italic>, <xref rid="bph13433-bib-0024" ref-type="ref">2009</xref>) and erythroferrone (Kautz <italic>et al.</italic>, <xref rid="bph13433-bib-0008" ref-type="ref">2014</xref>). Anaemia of chronic disease (ACD) is attributed to high circulating hepcidin concentrations that result in iron sequestration in reticuloendothelial cells such as macrophages and leads to iron&#x02010;restricted erythropoiesis in concert with shortened survival of red blood cells and suppression of erythropoiesis by inflammatory cytokines (Weiss and Goodnough, <xref rid="bph13433-bib-0029" ref-type="ref">2005</xref>). Currently, the treatment of ACD is difficult: many patients do not respond to erythropoiesis&#x02010;stimulating agents (MacDougall and Cooper, <xref rid="bph13433-bib-0011" ref-type="ref">2002</xref>; H&#x000f6;rl, <xref rid="bph13433-bib-0007" ref-type="ref">2007</xref>), while repeated administration of i.v. iron may result in iron overload (Rostoker <italic>et al.</italic>, <xref rid="bph13433-bib-0019" ref-type="ref">2012</xref>). By targeting hepcidin, a central pathophysiological process in ACD is addressed directly. Such pharmacological approaches might be more effective and safer than conventional treatments of ACD with erythropoiesis&#x02010;stimulating agents and i.v. iron.</p><p>Lexaptepid pegol (lexaptepid, laboratory code NOX&#x02010;H94) is a pegylated structured mirror&#x02010;image oligoribonucleotide (<sc>l</sc>&#x02010;RNA), the so&#x02010;called Spiegelmer&#x02009;&#x000ae;&#x02009;(Spiegelmer is a registered trademark of NOXXON Pharma AG), that binds to human hepcidin with high affinity (<italic>K</italic>
<sub>D</sub> = 0.65 &#x000b1; 0.06&#x000a0;nmol&#x000b7;L<sup>&#x02212;1</sup>) and thereby blocks its biological function as confirmed <italic>in vitro</italic> and <italic>in vivo</italic> (Schwoebel <italic>et al.</italic>, <xref rid="bph13433-bib-0021" ref-type="ref">2013</xref>). At the 5&#x02032;&#x02010;end, the <sc>l</sc>&#x02010;oligoribonucleotide terminates in a linker to which a branched 40&#x000a0;kDa monomethoxy polyethylene glycol (PEG) unit is covalently attached.</p><p>Here, we present the results of the first&#x02010;in&#x02010;human study with lexaptepid pegol. This study was conducted in 64 healthy subjects to assess the safety, tolerability and pharmacokinetics of single and repeated i.v. and s.c. doses of lexaptepid and to identify a dosage regimen suitable for clinical trials in patients with ACD.</p></sec><sec id="bph13433-sec-0007"><title>Methods</title><sec id="bph13433-sec-0008"><title>Subjects</title><p>The main selection criteria included healthy men and women of non&#x02010;childbearing potential aged 18&#x02013;65&#x000a0;years with a body mass index from 18 to 30&#x000a0;kg&#x000b7;m<sup>&#x02212;2</sup> and normal C&#x02010;reactive protein, clotting, haemoglobin, red cell indices, iron, transferrin saturation, and ferritin.</p></sec><sec id="bph13433-sec-0009"><title>Study design</title><p>This was a randomized, placebo&#x02010;controlled, double&#x02010;blind study of single and repeated doses in healthy volunteers. It was carried out by Hammersmith Medicines Research, London, UK, after approval by the <styled-content style="fixed-case">UK</styled-content> Medicines and Healthcare Products Regulatory Agency and the Health and Social Care Research Ethics Committee 1, Lisburn, <styled-content style="fixed-case">Northern Ireland</styled-content>. The study was conducted in accordance with good clinical practice, the Declaration of Helsinki from <styled-content style="fixed-case">October</styled-content> 1996 and the <styled-content style="fixed-case">European</styled-content> Medicines Agency guidelines on strategies to identify and mitigate risks for first&#x02010;in&#x02010;human clinical trials (EMA, <xref rid="bph13433-bib-0002" ref-type="ref">2007</xref>). All subjects provided written informed consent before participation. This trial was registered under NCT01372137 at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p><p>In the first part of the study, escalating single i.v. doses of lexaptepid (0.3, 0.6, 1.2, 2.4 or 4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> body weight) were infused over 15&#x000a0;min in a citrate buffer containing sucrose to five groups of eight men or women randomized to lexaptepid (<italic>n</italic> = 6) or the corresponding volume of 5% glucose as placebo control (<italic>n</italic> = 2). Dosing was staggered at each dose level: two subjects (one lexaptepid and one placebo) were initially dosed and, 48&#x000a0;h later, another two subjects were dosed. After another 48&#x000a0;h, the remaining four subjects were dosed on the same day. Safety data were reviewed after each step of the staggered dosing and before dose escalation. Pharmacokinetic (PK) and available pharmacodynamic data were also reviewed before dose escalation.</p><p>In the second part of the study, escalating repeated i.v. doses of lexaptepid (five doses of 0.6 or 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>) were infused over 15&#x000a0;min on alternate days to two groups of eight men randomized to lexaptepid (<italic>n</italic> = 6) or matching placebo (<italic>n</italic> = 2).</p><p>In the final part of the study, repeated doses of 36.5&#x000a0;mg lexaptepid were injected s.c. in a single cohort of eight healthy men (randomized 6:2 to receive lexaptepid or placebo). An initial s.c. dose was followed after 1&#x000a0;week by seven additional doses of lexaptepid on alternate days.</p><p>The follow&#x02010;up period was at least 4&#x000a0;weeks for all cohorts of subjects, and immunogenicity testing was carried out for up to 3&#x000a0;months.</p></sec><sec id="bph13433-sec-0010"><title>Safety assessments</title><p>Safety assessments were performed on admission to the clinical unit, before dosing and at scheduled intervals after dosing. They included monitoring for adverse events; physical examination; vital signs; clinical laboratory tests with full blood counts and standard biochemistry variables, prothrombin time, international normalized ratio, activated partial thromboplastin time, fibrinogen; 12&#x02010;lead ECG; and local tolerability at injection sites. Blood concentrations of IL&#x02010;6 and IL&#x02010;12 were also monitored after dosing. The single&#x02010;dose escalation part also included twin&#x02010;channel cardiac telemetry.</p></sec><sec id="bph13433-sec-0011"><title>Pharmacokinetic assessments</title><p>Venous blood and urine samples were collected for lexaptepid assay. Blood samples were collected before (<italic>t</italic> = 0) and at frequent intervals for up to 4&#x000a0;weeks after single and repeated i.v. and s.c. dosing. A 24&#x000a0;h urine collection was started immediately after dosing. Concentrations of lexaptepid in plasma and urine were assayed using a quantitative sandwich hybridization assay (Supporting Information) that detects full&#x02010;length oligonucleotides only, and does not differentiate between lexaptepid with and without bound hepcidin.</p><p>Pharmacokinetic parameters were derived by non&#x02010;compartmental methods using <sc>winnonlin professional</sc> version 6.2.1 software (Pharsight Corporation, St. Louis, MO, <styled-content style="fixed-case">USA</styled-content>). Parameters comprised maximum observed plasma concentration (<italic>C</italic>
<sub>max</sub>), the corresponding time to maximum concentration (<italic>t</italic>
<sub>max</sub>), area under the plasma concentration&#x02013;time curve to the last observed concentration (AUC<sub>0&#x02013;tz</sub>), terminal elimination half&#x02010;life (<italic>t</italic>
<sub>1/2</sub>), apparent volume of distribution at steady state (<italic>V</italic>
<sub>ss</sub>), total body clearance of drug from plasma (CL) and renal clearance (CL<sub>R</sub>). The initial elimination half&#x02010;life (<italic>t</italic>
<sub>1/2,ini</sub>) was calculated using a curve&#x02010;stripping method.</p></sec><sec id="bph13433-sec-0012"><title>Pharmacodynamic assessments</title><p>Plasma hepcidin concentrations were assayed by <ext-link ext-link-type="uri" xlink:href="http://Hepcidinanalysis.com">Hepcidinanalysis.com</ext-link> (Nijmegen, <styled-content style="fixed-case">The Netherlands</styled-content>) as hepcidin&#x02010;25 in samples taken at the same time points as the PK samples, using a combination of weak cation exchange chromatography and time&#x02010;of&#x02010;flight MS, with a hepcidin analogue as an internal standard (Kroot <italic>et al.</italic>, <xref rid="bph13433-bib-0010" ref-type="ref">2010</xref>; supplement to Schwoebel <italic>et al.</italic>, <xref rid="bph13433-bib-0021" ref-type="ref">2013</xref>). As with the lexaptepid assay, the hepcidin assay does not differentiate between free hepcidin and hepcidin bound to lexaptepid.</p><p>The following pharmacodynamic variables were also measured before (<italic>t</italic> = 0) and up to 28&#x000a0;days after dosing: reticulocyte Hb content (ADVIA 120, Siemens Healthcare, Frimley, <styled-content style="fixed-case">UK</styled-content>), serum ferritin, transferrin saturation, serum iron, and C&#x02010;reactive protein.</p></sec><sec id="bph13433-sec-0013"><title>Immunogenicity assessments</title><p>The presence of antibodies to lexaptepid in serum samples was assessed by a surface plasmon resonance method established at Eurofins Pharma Bioanalysis Services <styled-content style="fixed-case">UK</styled-content> Limited (Abingdon, <styled-content style="fixed-case">UK</styled-content>). The method is described in the Supporting Information.</p></sec><sec id="bph13433-sec-0014"><title>Statistical methods</title><p>This was a descriptive proof&#x02010;of&#x02010;principle study, so no formal calculation of sample size was performed. A statistician provided the randomization schedule. Safety and tolerability data were summarized using descriptive statistics, and were not subjected to formal analysis. All statistical analyses were performed using <sc>sas</sc> version 9.2 (SAS Institute Inc., Cary, NC, <styled-content style="fixed-case">USA</styled-content>) on a Windows XP personal computer. A power model was used to investigate the dose proportionality of AUC<sub>0&#x02013;tz</sub> and <italic>C</italic>
<sub>max</sub>. This model is defined as: <italic>Y</italic> = <italic>a</italic> &#x022c5; (dose)<sup><italic>b</italic></sup>. After logarithmic transformation, the power model was formulated as a linear model: ln(<italic>Y</italic>) = b &#x022c5; ln(dose) + error. The slope of the regression line (<italic>b</italic>) is 1 for dose proportionality and 0 for dose independence. Descriptive statistics were presented for the pharmacodynamic variables by dose group, including one pooled placebo group.</p></sec></sec><sec id="bph13433-sec-0015"><title>Results</title><sec id="bph13433-sec-0016"><title>Subjects</title><p>Of 64 healthy subjects (45 men and 19 women) overall, 40 were assigned to five subsequent groups of eight patients randomized to single i.v. infusions (<italic>n</italic> = 6) or placebo (<italic>n</italic> = 2) escalated from 0.3 through 0.6, 1.2, 2.4 and 4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid. Another two groups of eight subjects were administered five i.v. doses of either 0.6 or 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid versus placebo on alternate days over 10&#x000a0;days. The eighth group was treated with repeated s.c. injections of 36.5&#x000a0;mg lexaptepid (fixed dose) or placebo, administered as a pilot dose and a week later as seven injections on alternate days over 2&#x000a0;weeks. Baseline demographics were similar across all treatment groups. One subject (2%) withdrew consent from the i.v. 0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> repeated&#x02010;dose group, after receiving four doses of lexaptepid. The remaining 63 subjects (98%) completed the study.</p></sec><sec id="bph13433-sec-0017"><title>Safety</title><p>Lexaptepid was generally safe and well tolerated. The observed adverse events were mostly minor and transient and resolved spontaneously; their incidence and severity were similar over all treatment groups, with the exception of local injection site reactions after s.c. administration. Two subjects developed a skin rash at the sites of s.c. lexaptepid injections, starting 2&#x000a0;weeks after their final dose. The rash persisted for about 2&#x000a0;months and was treated with a topical steroid. Lymphocyte stimulation tests were negative in one subject and inconclusive in the other, so the exact aetiology of the rashes, be it irritation or sensitization, could not be determined. Other injection site reactions were injection site haematoma reported by three subjects (6%) after i.v. lexaptepid and by one subject (2%) after s.c. placebo injection. Presumed viral infection (mostly clinical nasopharyngitis: 14 subjects, 22%), headache (12 subjects, 19%), fatigue (6 subjects, 9%), oropharyngeal pain (5 subjects, 8%), dizziness (3 subjects, 5%), palpitation (2 subjects, 3%), dyshidrosis (2 subjects, 3%) and insomnia (2 subjects, 3%) were the only adverse events, whether related and unrelated to treatment, that occurred more than once. A single serious adverse event occurred 54&#x000a0;days after a single i.v. dose of 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid: after the sudden onset of occipital headache, a subject was admitted to hospital to exclude an intracerebral bleed. The adverse event was eventually diagnosed as muscular strain of the neck and deemed unrelated to treatment with lexaptepid. A list of all adverse events occurring after administration of the study medication is provided in the Supporting Information.</p><p>Mild and transient increases in liver transaminases (&#x0003c;2&#x000d7; upper limit of normal) in 12 asymptomatic subjects (25%) were observed after single doses of lexaptepid &#x02265;2.4&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> and after doses of 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> repeated on alternate days. These transaminase increases were not considered as adverse events. Coagulation, including prothrombin time, international normalized ratio, activated partial thromboplastin time, serum bilirubin, and eosinophil count were unchanged. Lexaptepid was not associated with clinically relevant changes in physical examination, vital signs, ECG, standard clinical laboratory tests or IL&#x02010;6 and IL&#x02010;12 results.</p></sec><sec id="bph13433-sec-0018"><title>Pharmacokinetics</title><p>All six subjects given lexaptepid from each dose group had enough data to allow calculation of reliable estimates of PK parameters and were included in the PK assessments.</p><p>The main PK parameters and the concentration&#x02013;time profiles after single i.v. infusion are summarized in Table&#x000a0;<xref rid="bph13433-tbl-0001" ref-type="table-wrap">1</xref> and Figure&#x000a0;<xref rid="bph13433-fig-0001" ref-type="fig">1</xref>. Peak plasma concentrations of lexaptepid were usually recorded within the first hour after dosing (0.25&#x02013;1&#x000a0;h). Mean <italic>C</italic>
<sub>max</sub> increased from 0.52 to 9.75&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup> after single i.v. doses of 0.3&#x02013;4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid respectively. Using a power model after logarithmic transformation, dose proportionality was concluded for <italic>C</italic>
<sub>max</sub>, as the mean slope in the power model analysis was 1.064 (0.991&#x02013;1.138&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup>, 95% confidence intervals). Supra&#x02010;proportional increases in the AUC occurred across the same dose range, with a mean slope for AUC<sub>0&#x02013;tz</sub> of 1.37 with the 95% confidence interval [1.21&#x02013;1.49] outside the 0.8&#x02013;1.25 interval. The dose of lexaptepid increased 16&#x02010;fold from 0.3 to 4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>, whereas AUC<sub>0&#x02013;tz</sub> increased by a factor of 45.</p><table-wrap id="bph13433-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Main pharmacokinetic parameters after single i.v. and s.c. administration of lexaptepid</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Dose/route</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>C</italic></bold>
<sub><bold>max</bold></sub>
<bold>(&#x003bc;mol</bold>
<bold>&#x000b7;L</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>AUC</bold>
<sub><bold>0&#x02013;tz</bold></sub>
<bold>(&#x003bc;mol</bold>
<bold>&#x000b7;L</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>&#x000b7;h</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>t</italic></bold>
<sub><bold>1/2</bold></sub>
<bold>(h)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>CL (</bold>
<bold>mL&#x000b7;h</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>V</italic></bold>
<sub><bold>ss</bold></sub>
<bold>(L)</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">0.3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>/i.v.</td><td align="left" valign="top" rowspan="1" colspan="1">0.517 (18.2)</td><td align="left" valign="top" rowspan="1" colspan="1">4.71 (76.4)</td><td align="left" valign="top" rowspan="1" colspan="1">14.1 (81.0)</td><td align="left" valign="top" rowspan="1" colspan="1">293 (72.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5.01 (42.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>/i.v.</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 (34.1)</td><td align="left" valign="top" rowspan="1" colspan="1">12.2 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">15.4 (85.8)</td><td align="left" valign="top" rowspan="1" colspan="1">229 (37.4)</td><td align="left" valign="top" rowspan="1" colspan="1">4.47 (41.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>/i.v.</td><td align="left" valign="top" rowspan="1" colspan="1">2.16 (12.0)</td><td align="left" valign="top" rowspan="1" colspan="1">29.8 (22.7)</td><td align="left" valign="top" rowspan="1" colspan="1">22.4 (38.9)</td><td align="left" valign="top" rowspan="1" colspan="1">184 (19.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4.08 (28.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.4&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>/i.v.</td><td align="left" valign="top" rowspan="1" colspan="1">4.70 (16.0)</td><td align="left" valign="top" rowspan="1" colspan="1">79.3 (14.5)</td><td align="left" valign="top" rowspan="1" colspan="1">23.2 (19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">145 (25.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3.63 (33.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>/i.v.</td><td align="left" valign="top" rowspan="1" colspan="1">9.75 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">211 (12.4)</td><td align="left" valign="top" rowspan="1" colspan="1">26.1 (12.2)</td><td align="left" valign="top" rowspan="1" colspan="1">115 (21.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3.30 (27.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">38.5&#x000a0;mg/s.c.</td><td align="left" valign="top" rowspan="1" colspan="1">0.0898 (92.3)</td><td align="left" valign="top" rowspan="1" colspan="1">8.14 (84.2)</td><td align="left" valign="top" rowspan="1" colspan="1">43.0 (57.1)</td><td align="left" valign="top" rowspan="1" colspan="1">n.d.</td><td align="left" valign="top" rowspan="1" colspan="1">n.d.</td></tr></tbody></table><table-wrap-foot><fn id="bph13433-note-0002"><p>Data shown are geometric means (with geometric coefficient of variation) for <italic>n</italic> = 6 subjects. <italic>C</italic>
<sub>max</sub>, maximum observed lexaptepid plasma concentration; AUC<sub>0&#x02013;tz</sub>, area under the plasma concentration&#x02013;time curve to the last observed concentration; <italic>t</italic>
<sub>1/2,</sub> terminal elimination half&#x02010;life; CL, plasma clearance; <italic>V</italic>
<sub>ss</sub>, volume of distribution at steady state; n.d., not determined.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="bph13433-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Concentration&#x02013;time profiles of lexaptepid and hepcidin&#x02010;25 in plasma after single i.v. administration of lexaptepid. Lexaptepid and hepcidin data are expressed as geometric means of six subjects per dose level.</p></caption><graphic id="nlm-graphic-1" xlink:href="BPH-173-1580-g001"/></fig><p>Systemic plasma clearance (CL) was low and decreased from 293 to 115&#x000a0;mL&#x000b7;h<sup>&#x02212;1</sup> as the dose of lexaptepid increased. Renal clearance (CL<sub>R</sub>) ranged from 5.47 to 7.00&#x000a0;mL&#x000b7;h<sup>&#x02212;1</sup> and was low compared with CL. The apparent volume of distribution at steady state (<italic>V</italic>
<sub>ss</sub>) decreased from 5.0 to 3.3&#x000a0;L with increasing dose, but remained within the range of the plasma volume. The lexaptepid plasma concentration&#x02013;time curve showed a biphasic elimination profile, with an initial rapid decline followed by a slower terminal elimination phase (Figure&#x000a0;<xref rid="bph13433-fig-0001" ref-type="fig">1</xref>). In some subjects with particularly low hepcidin concentrations, the slower elimination phase was absent (data not shown).</p><p>Rapid decrease in plasma concentrations within the first 8&#x000a0;h after dosing was characterized by a dose&#x02010;dependent initial half&#x02010;life (<italic>t</italic>
<sub>1/2,ini</sub>) of 1.8&#x02013;8.0&#x000a0;h. The terminal half&#x02010;life (<italic>t</italic>
<sub>1/2</sub>) increased dose&#x02010;dependently from 14.1 to 26.1&#x000a0;h. Urinary excretion of unchanged full&#x02010;length lexaptepid during the first 24&#x000a0;h after dosing increased from 1.35 to 3.69% with the dose of lexaptepid.</p><p>After repeated i.v. administration of 0.6 or 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid on alternate days (Figure&#x000a0;<xref rid="bph13433-fig-0002" ref-type="fig">2</xref>), the plasma concentration remained nearly constant, as judged by <italic>C</italic>
<sub>max</sub> and AUC after first and last doses. Mean trough concentrations determined at 48&#x000a0;h post&#x02010;dose were similar for all dose administrations at each of the two dose levels (0.09&#x02013;0.11&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup> after 0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> and 0.14&#x02013;0.20&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup> after 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>). The PK parameters after repeated i.v. doses of lexaptepid were similar to those after equivalent single i.v. doses; the ratios of AUC at steady state to AUC after a single dose were 0.90 and 1.21 for the 0.6 and 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> dose groups, respectively, with similar results for <italic>C</italic>
<sub>max</sub>.</p><fig fig-type="Figure" xml:lang="en" id="bph13433-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pharmacokinetic profiles of single and repeated i.v. administration of lexaptepid. Arrows indicate time of lexaptepid administration. After the first and last doses, a complete pharmacokinetic profile was determined; data of days 2, 4 and 6 represent pre&#x02010;dose concentrations. Data are expressed as geometric means of six subjects per dose level and are compared with data of single dose administration of 0.6 and 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>.</p></caption><graphic id="nlm-graphic-3" xlink:href="BPH-173-1580-g002"/></fig><p>The concentration&#x02013;time profile after single and repeated s.c. administration of 36.5&#x000a0;mg lexaptepid (fixed dose) is displayed in Figure&#x000a0;<xref rid="bph13433-fig-0003" ref-type="fig">3</xref> together with the corresponding hepcidin concentrations. The mean <italic>C</italic>
<sub>max</sub> of lexaptepid after the pilot dose was 0.090&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup> and was reached after 24&#x02013;51&#x000a0;h. The <italic>t</italic>
<sub>1/2</sub> after single and repeated s.c. doses was 43&#x000a0;h, which was longer than that after i.v. administration, most likely due to the continued influx of drug from the s.c. depot during the elimination phase. Repeated s.c. injections of 36.5&#x000a0;mg on alternate days resulted in moderate accumulation in plasma, with an accumulation ratio of 2.8 for <italic>C</italic>
<sub>max</sub>. Steady state was reached after three injections.</p><fig fig-type="Figure" xml:lang="en" id="bph13433-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Concentration&#x02013;time profiles of lexaptepid and hepcidin&#x02010;25 in plasma after single and repeated s.c. administration of lexaptepid. Arrows indicate injection of lexaptepid. Data shown for days 7 to 17 represent pre&#x02010;dose concentrations. Lexaptepid and hepcidin data are expressed as geometric means of six subjects.</p></caption><graphic id="nlm-graphic-5" xlink:href="BPH-173-1580-g003"/></fig></sec><sec id="bph13433-sec-0019"><title>Pharmacodynamics</title><sec id="bph13433-sec-0020"><title>Hepcidin</title><p>Mean plasma hepcidin concentration&#x02013;time profiles are presented together with the lexaptepid PK profiles in Figure&#x000a0;<xref rid="bph13433-fig-0003" ref-type="fig">3</xref> after single and repeated s.c. administration. Four subjects had low hepcidin at baseline and at subsequent time points in comparison with the rest of the study population. Mean plasma concentrations of total hepcidin increased dose&#x02010;dependently with lexaptepid treatment, without ever exceeding the plasma concentration of lexaptepid. Because the analytical method does not differentiate between free hepcidin and hepcidin bound to lexaptepid, and hepcidin concentration never exceeds the lexaptepid concentration, the hepcidin concentrations measured at later time points represent mainly bound hepcidin. The hepcidin production rate, estimated by the change in total plasma hepcidin concentration over time (&#x02206;<italic>c</italic>&#x02206;<italic>t</italic>
<sup>&#x02212;1</sup>) between pre&#x02010;dose and 4&#x000a0;h post&#x02010;lexaptepid administration, was largely constant over the dose range studied (Figure&#x000a0;<xref rid="bph13433-fig-0004" ref-type="fig">4</xref>).</p><fig fig-type="Figure" xml:lang="en" id="bph13433-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Production rates of hepcidin&#x02010;25 after single i.v. doses of lexaptepid. Hepcidin production rates were calculated based on the linear increase of total plasma hepcidin&#x02010;25 concentration between pre&#x02010;dose and 4&#x000a0;h after lexaptepid administration. Individual production rates are presented, with geometric means of six subjects. The 4&#x000a0;h data of one subject in the 0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> dose group, with concentration below the limit of quantitation, were excluded. Hepcidin production rates from subjects treated with LPS (van Eijk <italic>et al.</italic>, <xref rid="bph13433-bib-0026" ref-type="ref">2014</xref>) are shown for comparison.</p></caption><graphic id="nlm-graphic-7" xlink:href="BPH-173-1580-g004"/></fig></sec><sec id="bph13433-sec-0021"><title>Reticulocyte Hb content</title><p>No change was observed in the reticulocyte Hb content after single and repeated i.v. and s.c. dosing compared with placebo, and at no time point after dosing did it change by more than 30%.</p></sec><sec id="bph13433-sec-0022"><title>Iron metabolism variables</title><p>In the single&#x02010;i.v.&#x02010;dose groups, lexaptepid up to 0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> affected neither serum iron nor transferrin saturation nor serum ferritin. In the repeated&#x02010;dose group, however, increases of serum iron, transferrin saturation and serum ferritin were observed, even after the first dose of 0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid. After single doses of &#x02265;1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> and repeated doses of &#x02265;0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid, serum iron, transferrin saturation and serum ferritin increased dose&#x02010;dependently (Table&#x000a0;<xref rid="bph13433-tbl-0002" ref-type="table-wrap">2</xref> and Figures&#x000a0;<xref rid="bph13433-fig-0005" ref-type="fig">5</xref>, <xref rid="bph13433-fig-0006" ref-type="fig">6</xref>; Supporting Information, Figures S1, S2). Transferrin saturation rose above 80% in two subjects, one subject each treated with 1.2 and 4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> with peak transferrin saturation of 83.3 and 80.8%.</p><table-wrap id="bph13433-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>AUC for serum iron parameters after single i.v. doses of lexaptepid compared with baseline (means &#x000b1; SD)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="char" char="&#x000b1;" span="1"/><col align="char" char="&#x000b1;" span="1"/><col align="char" char="&#x000b1;" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="padding-left:10%" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Dose</bold>
<bold>(mg&#x000b7;kg</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>n</italic></bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Serum</bold>
<bold>iron AUC (&#x003bc;mol</bold>
<bold>&#x000b7;L</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>&#x000b7;h</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>TSAT AUC (%&#x000b7;h</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Serum ferritin AUC (&#x003bc;g</bold>
<bold>&#x000b7;L</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>&#x000b7;h</bold>
<sup><bold>&#x02212;1</bold></sup>
<bold>)</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Placebo</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">44.6&#x000a0;&#x000b1;&#x000a0;28.4</td><td align="left" valign="top" rowspan="1" colspan="1">62.5&#x000a0;&#x000b1;&#x000a0;41.0</td><td align="left" valign="top" rowspan="1" colspan="1">29.5&#x000a0;&#x000b1;&#x000a0;45.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.3</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">47.6&#x000a0;&#x000b1;&#x000a0;51.9</td><td align="left" valign="top" rowspan="1" colspan="1">82.2&#x000a0;&#x000b1;&#x000a0;76.9</td><td align="left" valign="top" rowspan="1" colspan="1">15.5&#x000a0;&#x000b1;&#x000a0;31.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.6</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">66.9&#x000a0;&#x000b1;&#x000a0;40.3</td><td align="left" valign="top" rowspan="1" colspan="1">111&#x000a0;&#x000b1;&#x000a0;60.1</td><td align="left" valign="top" rowspan="1" colspan="1">44.4&#x000a0;&#x000b1;&#x000a0;53.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1.2</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">193&#x000a0;&#x000b1;&#x000a0;53.7</td><td align="left" valign="top" rowspan="1" colspan="1">321&#x000a0;&#x000b1;&#x000a0;137</td><td align="left" valign="top" rowspan="1" colspan="1">125&#x000a0;&#x000b1;&#x000a0;206</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2.4</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">134&#x000a0;&#x000b1;&#x000a0;45.0</td><td align="left" valign="top" rowspan="1" colspan="1">239&#x000a0;&#x000b1;&#x000a0;97.8</td><td align="left" valign="top" rowspan="1" colspan="1">371&#x000a0;&#x000b1;&#x000a0;291</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4.8</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">225&#x000a0;&#x000b1;&#x000a0;138</td><td align="left" valign="top" rowspan="1" colspan="1">422&#x000a0;&#x000b1;&#x000a0;334</td><td align="left" valign="top" rowspan="1" colspan="1">644&#x000a0;&#x000b1;&#x000a0;670</td></tr></tbody></table><table-wrap-foot><fn id="bph13433-note-0003"><p>Area under the data&#x02013;time curve above baseline from time 0 to 24&#x000a0;h after the last dose. TSAT, transferrin saturation.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="bph13433-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Serum iron profiles after single i.v. doses of lexaptepid.</p></caption><graphic id="nlm-graphic-9" xlink:href="BPH-173-1580-g005"/></fig><fig fig-type="Figure" xml:lang="en" id="bph13433-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Mean serum iron concentrations after repeated i.v. doses of lexaptepid. After the first and last doses, a complete profile was determined. Data at days 2, 4 and 6 represent pre&#x02010;dose concentrations. Arrows indicate lexaptepid administration.</p></caption><graphic id="nlm-graphic-11" xlink:href="BPH-173-1580-g006"/></fig></sec></sec><sec id="bph13433-sec-0023"><title>Immunogenicity</title><p>No antibodies specific to the oligonucleotide chain of lexaptepid were detected at any point during the study. Antibodies specific to the PEG moiety were detected in pre&#x02010;dose samples with high inter&#x02010;individual variability. After treatment with lexaptepid, anti&#x02010;drug antibody responses increased above the calculated cut point of +20.5% in 10 subjects (21.3%) after lexaptepid in a total of 18 samples (16.8%) and in four subjects (25%) after placebo in a total of four samples (11.1%). The lack of difference in the number of positive samples between the individual dose groups, irrespective of dose strength, dosing schedule or dosing route, suggests that those effects were not related to treatment with lexaptepid. The presence of anti&#x02010;PEG antibodies did not affect the pharmacodynamic effect on serum iron or the PK profile of lexaptepid, as supported by the lack of correlation between pre&#x02010;existing or induced antibodies and the rate of lexaptepid plasma elimination (data not shown).</p></sec></sec><sec id="bph13433-sec-0024"><title>Discussion and conclusions</title><p>This first&#x02010;in&#x02010;human study with lexaptepid showed that it was safe and generally well tolerated: The main safety findings after i.v. administration were mild and transient increases in liver transaminases, which were observed when single lexaptepid doses were &#x02265;2.4&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>, or repeated doses were 1.2&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup> on alternate days, corresponding to a weekly dose of 4.2&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup>. i.v. treatment with lexaptepid had no effect on adverse events compared with placebo. After s.c. administration, two subjects developed local reactions, after a 2&#x02010;week interval, related to lexaptepid treatment. At present, the contribution of lexaptepid itself or the sucrose&#x02010;containing formulation to these dermal reactions is unclear.</p><p>The pharmacokinetics of lexaptepid after short i.v. infusion over 15&#x000a0;min were characterized by a dose&#x02010;proportional increase in maximum plasma concentrations, observed within 1&#x000a0;h after administration, and a slightly supra&#x02010;proportional increase in systemic exposure over the dose range studied. After s.c. administration, peak concentrations were significantly delayed until between 24 and 48&#x000a0;h after injection. Lexaptepid did not accumulate after repeated i.v. infusions of 0.6&#x02013;1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup>, but moderate accumulation occurred after repeated s.c. injection of lexaptepid. Steady state was reached after three of the eight alternate daily s.c. injections of 36.5&#x000a0;mg. A mean <italic>C</italic>
<sub>max</sub> of about 0.3&#x000a0;&#x003bc;mol&#x000b7;L<sup>&#x02212;1</sup> was attained at 12&#x000a0;h after the final dose. The apparent volume of distribution was in the range of 3&#x02013;5&#x000a0;L, corresponding closely to the intravascular plasma volume. Plasma clearance of lexaptepid was low (&#x0003c;300&#x000a0;mL&#x000b7;h<sup>&#x02212;1</sup>) and seemed to decrease further with increasing lexaptepid dose. The CL<sub>R</sub> calculated from excretion of unchanged Spiegelmer in urine did not exceed 7&#x000a0;mL&#x000b7;h<sup>&#x02212;1</sup>. This represented a renally eliminated fraction of less than 4% over the first 24&#x000a0;h after dosing. The discrepancy between CL and CL<sub>R</sub> points to an alternative route of elimination. In cynomolgus monkeys, vacuolated macrophages, presumably containing the pegylated Spiegelmer, were identified by histopathological examination in various organs, including the liver and spleen (data not shown). The elimination was mostly biphasic, with a fast <italic>t</italic>
<sub>1/2,ini</sub> and a <italic>t</italic>
<sub>1/2</sub> of approximately 24&#x000a0;h. The absence of the slower elimination phase in some subjects with low hepcidin concentrations may indicate that the elimination of lexaptepid is slower once it binds hepcidin. The <italic>t</italic>
<sub>1/2</sub> at lower doses may have been underestimated due to the shorter time to the last measurable drug concentration in the lower&#x02010;dose groups, which was 48&#x02013;96&#x000a0;h in the 0.3&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> dose group, compared with 240&#x000a0;h in the 4.8&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> dose group due to the limited sensitivity of the PK assay. As a result, the computation of <italic>t</italic>
<sub>1/2</sub> using at least four points of the terminal PK curve resulted in the interference by the faster <italic>t</italic>
<sub>1/2,ini</sub> in the lower&#x02010;dose groups and hence the underestimation of <italic>t</italic>
<sub>1/2</sub> and possibly also of the systemic exposure.</p><p>After administration of lexaptepid, total hepcidin increased in plasma. This increase represented hepcidin bound to the Spiegelmer and protected from plasma elimination. Peak concentrations of total hepcidin increased dose&#x02010;dependently, but hepcidin never exceeded the concentration of lexaptepid on a molar basis. Until approaching saturation of the binding capacity of lexaptepid, the increase in the hepcidin concentration was linear (defined as &#x02018;production rate&#x02019;) and independent of the dose of lexaptepid. Similar dose&#x02010;dependent changes in total hepcidin concentrations, that is, constant increase until saturation of the binding capacity and dose&#x02010;dependent peak concentration, were observed in cynomolgus monkeys treated with the anti&#x02010;hepcidin antibody Ab 12B9m (Xiao <italic>et al.</italic>, <xref rid="bph13433-bib-0031" ref-type="ref">2010</xref>). These findings suggest that hepcidin production is not induced by lexaptepid and that hepcidin is efficiently captured by lexaptepid, as further supported by the pharmacodynamic effects on iron variables. In contrast, after endotoxin&#x02010;induced inflammation in healthy subjects, the increase in serum hepcidin was approximately four times faster, suggestive of a higher hepcidin production rate. Even under these conditions, a single i.v. dose of 1.2&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> lexaptepid was able to inactivate the effects of hepcidin (van Eijk <italic>et al.</italic>, <xref rid="bph13433-bib-0026" ref-type="ref">2014</xref>).</p><p>Serum iron and transferrin saturation increased dose&#x02010;dependently after i.v. doses of lexaptepid of 0.6&#x000a0;mg&#x000b7;kg<sup>&#x02212;1</sup> or higher. Elevations of transferrin saturation above 80% were rare, indicating a low risk of the occurrence of toxic iron species such as non&#x02010;transferrin&#x02010;bound iron and labile plasma iron (de Swart, <italic>Haematologica</italic>, <xref rid="bph13433-bib-0033" ref-type="ref">2016</xref>). Increases in iron and transferrin saturation are the expected result of the elevated release of intracellular iron into the circulation by increased ferroportin activity. In the investigated population of healthy subjects with normochromic and normocytic reticulocytes and mature red blood cells, the increased iron availability did not result in an elevation of the haemoglobin load of reticulocytes, as shown by constant reticulocyte haemoglobin. Serum ferritin increased consistently and dose&#x02010;dependently after single doses of lexaptepid. Under conditions of elevated iron stores in the reticuloendothelial system (RES), the inhibition of hepcidin should release intracellular iron from the RES and thus, over time, should decrease serum ferritin concentrations (Cohen <italic>et al.</italic>, <xref rid="bph13433-bib-0003" ref-type="ref">2010</xref>), as observed in a study in cancer patients with ACD and high baseline ferritin who were treated with lexaptepid over a period of 4&#x000a0;weeks (Georgiev <italic>et al.</italic>, <xref rid="bph13433-bib-0006" ref-type="ref">2014</xref>). Therefore, serum ferritin increases observed in the present study are not likely to reflect cellular ferritin&#x02010;bound iron stores. The cause of the increase in serum ferritin would be merely speculation, as despite its long history of use in the assessment of body iron stores, the source and detailed secretory pathway of serum ferritin from cells are not completely understood (Wang <italic>et al.</italic>, <xref rid="bph13433-bib-0028" ref-type="ref">2010</xref>).</p><p>Currently, no drug acting specifically on the hepcidin&#x02013;ferroportin axis is approved for routine clinical use. The anti&#x02010;IL&#x02010;6 receptor antibody tocilizumab, approved for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, was effective in reducing hepcidin production and elevating haemoglobin in patients with Castleman disease, characterized by high IL&#x02010;6 (Song <italic>et al.</italic>, <xref rid="bph13433-bib-0022" ref-type="ref">2010</xref>). Tocilizumab is, however, unsuitable to treat ACD due to its immunosuppressive effects.</p><p>Several drugs are in development to inhibit hepcidin production, to bind and inactivate hepcidin or to inhibit the interaction between hepcidin and ferroportin, as reviewed by Fung and Nemeth (<xref rid="bph13433-bib-0004" ref-type="ref">2013</xref>). Among these, an antibody (LY2787106) and an anticalin (PRS&#x02010;080) targeting hepcidin and an antibody targeting ferroportin (LY2928057) (Witcher <italic>et al.</italic>, <xref rid="bph13433-bib-0030" ref-type="ref">2013</xref>) are in clinical development. These compounds have shown the expected pharmacodynamic effects on serum iron in animals. Clinical data from healthy subjects and cancer patients were presented that confirm their ability to increase serum iron concentrations (Moebius <italic>et al.</italic>, <xref rid="bph13433-bib-0012" ref-type="ref">2015</xref>; Vadhan&#x02010;Raj <italic>et al.</italic>, <xref rid="bph13433-bib-0027" ref-type="ref">2015</xref>). In addition, with its lower immunogenic potential, the Spiegelmer lexaptepid may have an advantage over antibodies in a chronic treatment setting.</p><p>In conclusion, in this first&#x02010;in&#x02010;human study, lexaptepid showed a favourable safety, PK and pharmacodynamic profile. Offering a new therapeutic approach, it may complement the armamentarium of anaemia treatment, reduce doses of erythropoiesis&#x02010;stimulating agents and i.v. iron and improve the safety and efficacy of anaemia treatment. Clinical studies in ACD in cancer patients and in dialysis patients are ongoing and should provide further evidence of the value of the hepcidin&#x02013;ferroportin axis as a target for treatment of ACD.</p></sec><sec id="bph13433-sec-0026"><title>Author contributions</title><p>M.B., S.W. and B.C. conducted the clinical study, interpreted the findings and wrote the manuscript. S.Z. and S.V. planned, performed and interpreted the pharmacokinetics, monitored hepcidin measurements and edited the manuscript. D.W.S. supervised measurements of hepcidin, interpreted findings and edited the manuscript. L.S., F.S. and K.R. designed the study; gathered, cleaned and interpreted the data; and edited the manuscript.</p></sec><sec id="bph13433-sec-0027"><title>Conflict of interest</title><p>This study was sponsored by NOXXON Pharma AG, Berlin, <styled-content style="fixed-case">Germany</styled-content>. M.B., S.W. and B.C. are employees of Hammersmith Medicines Research. S.Z., S.V., L.S., F.S. and K.R. are employees of NOXXON Pharma AG. D.W.S. is involved in the <ext-link ext-link-type="uri" xlink:href="http://Hepcidinanalysis.com">Hepcidinanalysis.com</ext-link> initiative, by which the Radboud University Nijmegen Medical Center offers high&#x02010;quality hepcidin measurement to the scientific and medical community. The other authors have no conflicts of interest to declare.</p></sec><sec id="bph13433-sec-0030"><title>Declaration of transparency and scientific rigour</title><p>This <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.13405/abstract">Declaration</ext-link> acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organizations engaged with supporting research.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bph.13433">http://dx.doi.org/10.1111/bph.13433</ext-link>
</p><p>
<bold>Figure S1</bold> Serum ferritin: change from baseline after single administration of lexaptepid pegol</p><p>
<bold>Figure S2</bold> Transferrin saturation: change from baseline after single administration of lexaptepid pegol</p><p>
<bold>Table S1</bold> Overview of treatment&#x02010;emergent adverse events</p></supplementary-material><supplementary-material content-type="local-data" id="bph13433-supitem-0001"><caption><p>Supporting info item</p></caption><media xlink:href="BPH-173-1580-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="bph13433-sec-0025"><title>Acknowledgements</title><p>The study was funded by NOXXON Pharma AG with grant support within the programme <italic>KMU&#x02010;innovativ</italic> from the <styled-content style="fixed-case">German</styled-content> Federal Ministry of Education and Research (BMBF) for the preclinical and early clinical development of lexaptepid. We thank Coby Laarakkers for measurement of total hepcidin&#x02010;25 and Frauke Friedrichs of MARCO GmbH &#x00026; Co. KG for statistical analyses.</p></ack><ref-list id="bph13433-bibl-0001" content-type="cited-references"><title>References</title><ref id="bph13433-bib-0001"><mixed-citation publication-type="journal" id="bph13433-cit-0002">
<string-name>
<surname>Alexander</surname>
<given-names>SPH</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Marrion</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Benson</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Faccenda</surname>
<given-names>E</given-names>
</string-name>
<italic>et al.</italic> (<year>2015</year>). <article-title>The Concise Guide to PHARMACOLOGY 2015/16: Transporters</article-title>. <source>Br J Pharmacol</source>
<volume>172</volume>: <fpage>6110</fpage>&#x02013;<lpage>6202</lpage>.<pub-id pub-id-type="pmid">26650446</pub-id></mixed-citation></ref><ref id="bph13433-bib-0002"><mixed-citation publication-type="miscellaneous" id="bph13433-cit-0003">
<collab collab-type="authors">EMA</collab>
(<year>2007</year>). <article-title>Guideline on strategies to identify and mitigate risks for first&#x02010;in&#x02010;human clinical trials with investigational medicinal products</article-title>. EMEA/CHMP/SWP/28367/28307: <styled-content style="fixed-case">European</styled-content> Medicines Agency.</mixed-citation></ref><ref id="bph13433-bib-0003"><mixed-citation publication-type="journal" id="bph13433-cit-0004">
<string-name>
<surname>Cohen</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Leichtmann&#x02010;Bardoogo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Crooks</surname>
<given-names>DR</given-names>
</string-name>
<italic>et al.</italic> (<year>2010</year>). <article-title>Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway</article-title>. <source>Blood</source>
<volume>116</volume>: <fpage>1574</fpage>&#x02013;<lpage>1584</lpage>.<pub-id pub-id-type="pmid">20472835</pub-id></mixed-citation></ref><ref id="bph13433-bib-0033"><mixed-citation publication-type="journal" id="bph13433-cit-0034">
<string-name>
<surname>de Swart</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hendriks</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>van der Vorm</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Cabantchik</surname>
<given-names>ZI</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Hod</surname>
<given-names>EA</given-names>
</string-name>
<italic>et al.</italic> (<year>2016</year>). <article-title>Second international round robin for the quantification of serum non&#x02010;transferrin&#x02010;bound iron and labile plasma iron in patients with iron&#x02010;overload disorders</article-title>. <source>Haematologica</source>
<volume>101</volume>: <fpage>38</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">26385212</pub-id></mixed-citation></ref><ref id="bph13433-bib-0004"><mixed-citation publication-type="journal" id="bph13433-cit-0005">
<string-name>
<surname>Fung</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nemeth</surname>
<given-names>E</given-names>
</string-name> (<year>2013</year>). <article-title>Manipulation of the hepcidin pathway for therapeutic purposes</article-title>. <source>Haematologica</source>
<volume>98</volume>: <fpage>1667</fpage>&#x02013;<lpage>1676</lpage>.<pub-id pub-id-type="pmid">24186312</pub-id></mixed-citation></ref><ref id="bph13433-bib-0005"><mixed-citation publication-type="journal" id="bph13433-cit-0006">
<string-name>
<surname>Ganz</surname>
<given-names>T</given-names>
</string-name> (<year>2003</year>). <article-title>Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation</article-title>. <source>Blood</source>
<volume>102</volume>: <fpage>783</fpage>&#x02013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">12663437</pub-id></mixed-citation></ref><ref id="bph13433-bib-0006"><mixed-citation publication-type="journal" id="bph13433-cit-0007">
<string-name>
<surname>Georgiev</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lazaroiu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ocroteala</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grudeva&#x02010;Popova</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gheorghita</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Vasilica</surname>
<given-names>M</given-names>
</string-name>
<italic>et al.</italic> (<year>2014</year>). <article-title>Abstract 3847: the anti&#x02010;hepcidin Spiegelmer&#x000ae; lexaptepid pegol (NOX&#x02010;H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: a phase II pilot study</article-title>. <source>Cancer Res</source>
<volume>74</volume>: <fpage>3847</fpage>.</mixed-citation></ref><ref id="bph13433-bib-0007"><mixed-citation publication-type="journal" id="bph13433-cit-0008">
<string-name>
<surname>H&#x000f6;rl</surname>
<given-names>WH</given-names>
</string-name> (<year>2007</year>). <article-title>Iron therapy for renal anemia: how much needed, how much harmful?</article-title>
<source>Pediatr Nephrol</source>
<volume>22</volume>: <fpage>480</fpage>&#x02013;<lpage>489</lpage>.<pub-id pub-id-type="pmid">17206511</pub-id></mixed-citation></ref><ref id="bph13433-bib-0008"><mixed-citation publication-type="journal" id="bph13433-cit-0009">
<string-name>
<surname>Kautz</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Valore</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>Rivella</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nemeth</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ganz</surname>
<given-names>T</given-names>
</string-name> (<year>2014</year>). <article-title>Identification of erythroferrone as an erythroid regulator of iron metabolism</article-title>. <source>Nat Genet</source>
<volume>46</volume>: <fpage>678</fpage>&#x02013;<lpage>684</lpage>.<pub-id pub-id-type="pmid">24880340</pub-id></mixed-citation></ref><ref id="bph13433-bib-0009"><mixed-citation publication-type="journal" id="bph13433-cit-0010">
<string-name>
<surname>Krause</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Neitz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Magert</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Schulz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Forssmann</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Schulz&#x02010;Knappe</surname>
<given-names>P</given-names>
</string-name>
<italic>et al.</italic> (<year>2000</year>). <article-title>LEAP&#x02010;1, a novel highly disulfide&#x02010;bonded human peptide, exhibits antimicrobial activity</article-title>. <source>FEBS Lett</source>
<volume>480</volume>: <fpage>147</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">11034317</pub-id></mixed-citation></ref><ref id="bph13433-bib-0010"><mixed-citation publication-type="journal" id="bph13433-cit-0011">
<string-name>
<surname>Kroot</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Laarakkers</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Geurts&#x02010;Moespot</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Grebenchtchikov</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pickkers</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>van Ede</surname>
<given-names>AE</given-names>
</string-name>
<italic>et al.</italic> (<year>2010</year>). <article-title>Immunochemical and mass&#x02010;spectrometry&#x02010;based serum hepcidin assays for iron metabolism disorders</article-title>. <source>Clin Chem</source>
<volume>56</volume>: <fpage>1570</fpage>&#x02013;<lpage>1579</lpage>.<pub-id pub-id-type="pmid">20739637</pub-id></mixed-citation></ref><ref id="bph13433-bib-0011"><mixed-citation publication-type="journal" id="bph13433-cit-0012">
<string-name>
<surname>MacDougall</surname>
<given-names>IC</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>AC</given-names>
</string-name> (<year>2002</year>). <article-title>Erythropoietin resistance: the role of inflammation and pro&#x02010;inflammatory cytokines</article-title>. <source>Nephrol Dial Transplant</source>
<volume>17</volume> (<issue>Suppl 11</issue>): <fpage>39</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">12386257</pub-id></mixed-citation></ref><ref id="bph13433-bib-0012"><mixed-citation publication-type="miscellaneous" id="bph13433-cit-0013">
<string-name>
<surname>Moebius</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Feuerer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Fenzl</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van Swelm</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Swinkels</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Hohlbaum</surname>
<given-names>A</given-names>
</string-name> (<year>2015</year>) <article-title>Abstract 536: a phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS&#x02010;080#022. Results from a randomized, placebo controlled, double&#x02010;blind study following single administration to healthy subjects</article-title>. 57th ASH Annual Meeting &#x00026; Exposition Dec 5&#x02013;8, 2015.</mixed-citation></ref><ref id="bph13433-bib-0013"><mixed-citation publication-type="journal" id="bph13433-cit-0014">
<string-name>
<surname>Nemeth</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ganz</surname>
<given-names>T</given-names>
</string-name> (<year>2006</year>). <article-title>Regulation of iron metabolism by hepcidin</article-title>. <source>Annu Rev Nutr</source>
<volume>26</volume>: <fpage>323</fpage>&#x02013;<lpage>342</lpage>.<pub-id pub-id-type="pmid">16848710</pub-id></mixed-citation></ref><ref id="bph13433-bib-0014"><mixed-citation publication-type="journal" id="bph13433-cit-0015">
<string-name>
<surname>Nemeth</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tuttle</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Powelson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vaughn</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Donovan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ward</surname>
<given-names>DM</given-names>
</string-name>
<italic>et al.</italic> (<year>2004</year>). <article-title>Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization</article-title>. <source>Science</source>
<volume>306</volume>: <fpage>2090</fpage>&#x02013;<lpage>2093</lpage>.<pub-id pub-id-type="pmid">15514116</pub-id></mixed-citation></ref><ref id="bph13433-bib-0015"><mixed-citation publication-type="journal" id="bph13433-cit-0016">
<string-name>
<surname>Park</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Valore</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>Waring</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ganz</surname>
<given-names>T</given-names>
</string-name> (<year>2001</year>). <article-title>Hepcidin, a urinary antimicrobial peptide synthesized in the liver</article-title>. <source>J Biol Chem</source>
<volume>276</volume>: <fpage>7806</fpage>&#x02013;<lpage>7810</lpage>.<pub-id pub-id-type="pmid">11113131</pub-id></mixed-citation></ref><ref id="bph13433-bib-0016"><mixed-citation publication-type="journal" id="bph13433-cit-0017">
<string-name>
<surname>Pawson</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Sharman</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Benson</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Faccenda</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>SPH</given-names>
</string-name>, <string-name>
<surname>Buneman</surname>
<given-names>OP</given-names>
</string-name>
<italic>et al.</italic> , NC&#x02010;IUPHAR(<year>2014</year>). <article-title>The IUPHAR/BPS Guide to PHARMACOLOGY: an expert&#x02010;driven knowledge base of drug targets and their ligands</article-title>. <source>Nucl Acids Res</source>
<volume>42</volume> (<issue>Database Issue</issue>): <fpage>D1098</fpage>&#x02013;<lpage>D1106</lpage>.<pub-id pub-id-type="pmid">24234439</pub-id></mixed-citation></ref><ref id="bph13433-bib-0017"><mixed-citation publication-type="journal" id="bph13433-cit-0018">
<string-name>
<surname>Pigeon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ilyin</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Courselaud</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Leroyer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Turlin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Brissot</surname>
<given-names>P</given-names>
</string-name>
<italic>et al.</italic> (<year>2001</year>). <article-title>A new mouse liver&#x02010;specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload</article-title>. <source>J Biol Chem</source>
<volume>276</volume>: <fpage>7811</fpage>&#x02013;<lpage>7819</lpage>.<pub-id pub-id-type="pmid">11113132</pub-id></mixed-citation></ref><ref id="bph13433-bib-0018"><mixed-citation publication-type="journal" id="bph13433-cit-0019">
<string-name>
<surname>Preza</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Pinon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ganz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nemeth</surname>
<given-names>E</given-names>
</string-name> (<year>2013</year>). <article-title>Cellular catabolism of the iron&#x02010;regulatory peptide hormone hepcidin</article-title>. <source>PLoS One</source>
<volume>8</volume>: e58934.</mixed-citation></ref><ref id="bph13433-bib-0019"><mixed-citation publication-type="journal" id="bph13433-cit-0020">
<string-name>
<surname>Rostoker</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Griuncelli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Loridon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Couprie</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Benmaadi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bounhiol</surname>
<given-names>C</given-names>
</string-name>
<italic>et al.</italic> (<year>2012</year>). <article-title>Hemodialysis&#x02010;associated hemosiderosis in the era of erythropoiesis&#x02010;stimulating agents: a MRI study</article-title>. <source>Am J Med</source>
<volume>125</volume>: <fpage>991</fpage>&#x02013;<lpage>999.e991</lpage>.<pub-id pub-id-type="pmid">22998881</pub-id></mixed-citation></ref><ref id="bph13433-bib-0020"><mixed-citation publication-type="journal" id="bph13433-cit-0021">
<string-name>
<surname>Roy</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Mak</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Akpan</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Losyev</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zurakowski</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Andrews</surname>
<given-names>NC</given-names>
</string-name> (<year>2007</year>). <article-title>Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation</article-title>. <source>Blood</source>
<volume>109</volume>: <fpage>4038</fpage>&#x02013;<lpage>4044</lpage>.<pub-id pub-id-type="pmid">17218383</pub-id></mixed-citation></ref><ref id="bph13433-bib-0021"><mixed-citation publication-type="journal" id="bph13433-cit-0022">
<string-name>
<surname>Schwoebel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>van Eijk</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Zboralski</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sell</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Buchner</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Maasch</surname>
<given-names>C</given-names>
</string-name>
<italic>et al.</italic> (<year>2013</year>). <article-title>The effects of the anti&#x02010;hepcidin Spiegelmer NOX&#x02010;H94 on inflammation&#x02010;induced anemia in cynomolgus monkeys</article-title>. <source>Blood</source>
<volume>121</volume>: <fpage>2311</fpage>&#x02013;<lpage>2315</lpage>.<pub-id pub-id-type="pmid">23349391</pub-id></mixed-citation></ref><ref id="bph13433-bib-0022"><mixed-citation publication-type="journal" id="bph13433-cit-0023">
<string-name>
<surname>Song</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Tomosugi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kawabata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ishikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshizaki</surname>
<given-names>K</given-names>
</string-name> (<year>2010</year>). <article-title>Down&#x02010;regulation of hepcidin resulting from long&#x02010;term treatment with an anti&#x02010;IL&#x02010;6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease</article-title>. <source>Blood</source>
<volume>116</volume>: <fpage>3627</fpage>&#x02013;<lpage>3634</lpage>.<pub-id pub-id-type="pmid">20644113</pub-id></mixed-citation></ref><ref id="bph13433-bib-0023"><mixed-citation publication-type="journal" id="bph13433-cit-0024">
<string-name>
<surname>Swinkels</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Girelli</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Laarakkers</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kroot</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Campostrini</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kemna</surname>
<given-names>EH</given-names>
</string-name>
<italic>et al.</italic> (<year>2008</year>). <article-title>Advances in quantitative hepcidin measurements by time&#x02010;of&#x02010;flight mass spectrometry</article-title>. <source>PLoS One</source>
<volume>3</volume> e2706.</mixed-citation></ref><ref id="bph13433-bib-0024"><mixed-citation publication-type="journal" id="bph13433-cit-0025">
<string-name>
<surname>Tanno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Porayette</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sripichai</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Noh</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Byrnes</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bhupatiraju</surname>
<given-names>A</given-names>
</string-name>
<italic>et al.</italic> (<year>2009</year>). <article-title>Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells</article-title>. <source>Blood</source>
<volume>114</volume>: <fpage>181</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">19414861</pub-id></mixed-citation></ref><ref id="bph13433-bib-0025"><mixed-citation publication-type="journal" id="bph13433-cit-0026">
<string-name>
<surname>Tanno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bhanu</surname>
<given-names>NV</given-names>
</string-name>, <string-name>
<surname>Oneal</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Goh</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Staker</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>YT</given-names>
</string-name>
<italic>et al.</italic> (<year>2007</year>). <article-title>High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin</article-title>. <source>Nat Med</source>
<volume>13</volume>: <fpage>1096</fpage>&#x02013;<lpage>1101</lpage>.<pub-id pub-id-type="pmid">17721544</pub-id></mixed-citation></ref><ref id="bph13433-bib-0026"><mixed-citation publication-type="journal" id="bph13433-cit-0027">
<string-name>
<surname>van Eijk</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>John</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Schwoebel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Summo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vauleon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zollner</surname>
<given-names>S</given-names>
</string-name>
<italic>et al.</italic> (<year>2014</year>). <article-title>Effect of the antihepcidin Spiegelmer lexaptepid on inflammation&#x02010;induced decrease in serum iron in humans</article-title>. <source>Blood</source>
<volume>124</volume>: <fpage>2643</fpage>&#x02013;<lpage>2646</lpage>.<pub-id pub-id-type="pmid">25163699</pub-id></mixed-citation></ref><ref id="bph13433-bib-0027"><mixed-citation publication-type="miscellaneous" id="bph13433-cit-0028">
<string-name>
<surname>Vadhan&#x02010;Raj</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Abonour</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Slapak</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Tiu</surname>
<given-names>RV</given-names>
</string-name>, <italic>et al</italic> (<year>2015</year>). <article-title>Abstract 537: Phase 1 study of a hepcidin antagonist, LY2787106, in cancer&#x02010;associated anemia</article-title>. 57th ASH Annual Meeting &#x00026; Exposition Dec 5&#x02013;8, 2015.</mixed-citation></ref><ref id="bph13433-bib-0028"><mixed-citation publication-type="journal" id="bph13433-cit-0029">
<string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Knovich</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Coffman</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Torti</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Torti</surname>
<given-names>SV</given-names>
</string-name> (<year>2010</year>). <article-title>Serum ferritin: past, present and future</article-title>. <source>Biochim Biophys Acta</source>
<volume>1800</volume>: <fpage>760</fpage>&#x02013;<lpage>769</lpage>.<pub-id pub-id-type="pmid">20304033</pub-id></mixed-citation></ref><ref id="bph13433-bib-0029"><mixed-citation publication-type="journal" id="bph13433-cit-0030">
<string-name>
<surname>Weiss</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Goodnough</surname>
<given-names>LT</given-names>
</string-name> (<year>2005</year>). <article-title>Anemia of chronic disease</article-title>. <source>N Engl J Med</source>
<volume>352</volume>: <fpage>1011</fpage>&#x02013;<lpage>1023</lpage>.<pub-id pub-id-type="pmid">15758012</pub-id></mixed-citation></ref><ref id="bph13433-bib-0030"><mixed-citation publication-type="journal" id="bph13433-cit-0031">
<string-name>
<surname>Witcher</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>de Rosa</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Manetta</surname>
<given-names>J</given-names>
</string-name>
<italic>et al.</italic> (<year>2013</year>). <article-title>LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys</article-title>. <source>Blood</source>
<volume>122</volume>: <fpage>3433</fpage>.</mixed-citation></ref><ref id="bph13433-bib-0031"><mixed-citation publication-type="journal" id="bph13433-cit-0032">
<string-name>
<surname>Xiao</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Krzyzanski</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rose</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>M</given-names>
</string-name>
<italic>et al.</italic> (<year>2010</year>). <article-title>Pharmacokinetics of anti&#x02010;hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys</article-title>. <source>AAPS J</source>
<volume>12</volume>: <fpage>646</fpage>&#x02013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">20737261</pub-id></mixed-citation></ref></ref-list></back></article>